+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiac Tissue Engineering Market by Product Type, Application, Technology, End User, Cell Source - Global Forecast to 2030- Product Image
Cardiac Tissue Engineering Market by Product Type, Application, Technology, End User, Cell Source - Global Forecast to 2030- Product Image
Sale

Cardiac Tissue Engineering Market by Product Type, Application, Technology, End User, Cell Source - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014766
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cardiac Tissue Engineering Market grew from USD 10.45 billion in 2024 to USD 11.37 billion in 2025. It is expected to continue growing at a CAGR of 8.62%, reaching USD 17.18 billion by 2030.

Advancing Cardiac Health Through Engineered Solutions

Cardiac tissue engineering has emerged as a cornerstone of regenerative medicine, offering transformative potential to address heart disease, a leading cause of mortality worldwide. By integrating principles of cell biology, biomaterials science, and clinical practice, researchers are crafting biologically compatible constructs capable of restoring or replacing damaged myocardial tissue. This executive summary distills the most salient developments, market drivers, and strategic considerations shaping the cardiac tissue engineering landscape.

Recent advancements in biomimetic scaffolds, injectable hydrogels, and stem cell-based therapies have elevated the feasibility of repairing complex cardiac defects. Concurrently, regulatory agencies are refining pathways to facilitate clinical translation, while collaborations across academia, biotech, and healthcare providers are accelerating the journey from bench to bedside. This introduction outlines the scope, objectives, and methodology of our analysis, setting the stage for a deep dive into the market’s pivotal trends, segmentation insights, and regional dynamics.

Breakthrough Innovations Reshaping Cardiac Tissue Engineering

Breakthrough technologies and shifting regulatory paradigms are driving a transformational pivot within cardiac tissue engineering. High-resolution 3D bioprinting techniques now enable the fabrication of intricate vascular networks, while decellularized matrices provide native extracellular frameworks that enhance cellular integration and functional maturation. Stem cell therapies have matured beyond proof-of-concept, with induced pluripotent stem cells demonstrating robust potential for patient-specific myocardial repair.

These advances coincide with evolving reimbursement models that increasingly recognize the long-term value of regenerative interventions over chronic disease management. Public-private partnerships and consortia are fostering standardization of protocols, addressing scalability and cost-effectiveness challenges. As a result, the industry is witnessing a convergence of innovation, policy support, and capital influx, setting the stage for the next era of cardiac restoration.

Tariff Policy Dynamics Influencing Industry Economics

The imposition of new U.S. tariffs in 2025 has introduced additional layers of complexity for manufacturers, suppliers, and end users across the cardiac tissue engineering spectrum. Increased duties on imported biomaterials, reagents, and specialized equipment have elevated production costs and compressed profit margins. This has triggered a strategic reassessment of global supply chains, prompting many organizations to explore domestic sourcing or regional partnerships to mitigate exposure to tariff fluctuations.

Despite these headwinds, some companies have leveraged tariff-induced challenges as catalysts for vertical integration and localized manufacturing. By consolidating critical processes in tariff-free zones or investing in in-house polymer synthesis and cell culture capabilities, innovators have preserved cost competitiveness while safeguarding quality standards. Looking ahead, dynamic trade policy is expected to remain a key variable influencing investment decisions, collaborative ventures, and geographic expansion strategies.

Unlocking Market Potential Through Detailed Segmentation

A nuanced segmentation framework reveals distinct pockets of opportunity and differentiation across the cardiac tissue engineering market. Product type analysis highlights that bioartificial hearts, encompassing both partial and whole organ constructs, are accelerating advanced preclinical studies, whereas cardiac patches-spanning decellularized and electrospun variants-are garnering traction in minimally invasive surgical repair. Cardiac scaffolds, differentiated into biological and synthetic matrices, are being optimized for mechanical strength and biocompatibility, while injectable hydrogels, whether derived from natural or synthetic polymers, are emerging as versatile platforms for localized myocardial regeneration.

Examining applications underscores the critical role of heart valve regeneration strategies, from biologically derived leaflet remodeling to mechanical valve replacement innovations. Myocardial repair initiatives address congenital cardiac anomalies and post-infarction damage with tailored cell therapies and matrix-guided tissue remodeling. Vascular grafting remains a strategic focus, with coronary artery bypass and peripheral vascular repair benefiting from graft materials engineered to mimic native elasticity and promote endothelialization.

Technological segmentation illuminates the ascendancy of 3D bioprinting methods-extrusion, inkjet, and laser-assisted-that enable precise cell distribution and hierarchical architecture. Decellularized matrices leverage both tissue segment and whole organ decellularization techniques to preserve native biomechanics and signaling cues. Stem cell therapy approaches, drawing on embryonic, induced pluripotent, and mesenchymal sources, continue to refine differentiation protocols and immunomodulatory properties to enhance engraftment and functional integration.

End user perspectives reveal that biotechnology firms are driving early-stage innovation and process scale-up, while hospitals are increasingly piloting clinical applications and post-market studies. Pharmaceutical companies are partnering to integrate regenerative modules within drug development pipelines, and research institutes are spearheading foundational discoveries that inform next-generation platforms.

Cell source considerations differentiate strategies based on allogeneic donor cardiomyocytes and stromal cells, autologous cell harvests tailored to individual patients, and xenogeneic scaffolds derived from bovine or porcine origins. Each approach balances immunogenicity, availability, and regulatory complexity, shaping product development pathways and adoption curves.

Geographic Patterns Driving Industry Growth

Regional dynamics in the Americas continue to be shaped by robust R&D funding, supportive regulatory frameworks, and a growing network of regenerative medicine centers. The United States leads with numerous clinical trials and early commercial deployments, supported by government grants and tax incentives that lower barriers to entry. Latin American nations are forging collaborative agreements to build local capacity in biomanufacturing and clinical validation, thus expanding the continental footprint of cardiac tissue solutions.

In Europe, Middle East, and Africa, the regulatory landscape is characterized by harmonization efforts across the EU and adaptive pathways in select Gulf countries. European research consortia are advancing decellularized organ technologies and establishing centralized manufacturing facilities to serve multiple member states. Investment in regional hubs is enabling technology transfer to North African and sub-Saharan markets, where unmet cardiovascular needs are significant and growth potential remains underexploited.

The Asia-Pacific arena is experiencing accelerated commercialization driven by large patient populations and escalating healthcare expenditures. China and Japan are at the forefront of clinical adoption, propelled by strategic government initiatives and public-private partnerships. Southeast Asian nations are incrementally enhancing their regenerative medicine infrastructure, focusing on scalable bioprocessing and regulatory framework development. Across the region, an emphasis on cost-effective domestic solutions is spurring innovation in affordable scaffold materials and streamlined cell therapy platforms.

Competitive Landscape and Leading Innovators

The competitive landscape is populated by pioneering firms that span the continuum from early-stage research to clinical commercialization. Key innovators in biofabrication are advancing proprietary 3D bioprinters and bioink formulations to achieve vascularized, contractile tissue constructs. Leading contract development and manufacturing organizations have invested heavily in cleanroom facilities and automated workflows to support cGMP-compliant production of cellular therapies and scaffold materials.

Strategic alliances between pharmaceutical giants and regenerative technology companies are carving new niches, blending drug-device combinations with tissue engineering modalities. Research institutes are forging spinouts that translate groundbreaking discoveries in stem cell biology into venture-backed startups, attracting cross-border investments and accelerating global market entry. As a result, mid-sized enterprises agile enough to pivot on emerging data and large-scale players with established commercial networks are both vying for leadership positions, each leveraging unique strengths in technology, capital, or clinical access.

Strategic Roadmap for Stakeholder Success

To capitalize on the momentum in cardiac tissue engineering, stakeholders should prioritize integration of scalable manufacturing processes early in development to enable rapid clinical translation. Collaborative consortium models that unite academia, industry, and regulatory bodies can standardize validation protocols, mitigate technical risk, and share best practices. Embracing modular platform technologies, such as plug-and-play bioreactors and interchangeable biomaterial libraries, will enhance flexibility and reduce time to market.

Investments in real-world evidence collection and economic modeling are essential to demonstrate long-term value to payers and healthcare systems. Companies should cultivate strategic partnerships in key regions to navigate complex trade policies and localize supply chains. Finally, fostering multidisciplinary talent pools-combining expertise in bioengineering, clinical cardiology, regulatory affairs, and commercial strategy-will be critical to sustaining innovation and driving adoption of next-generation cardiac therapies.

Rigorous Methodology Underpinning Insights

This analysis synthesizes primary interviews with leading clinicians, academic researchers, and industry executives, complemented by secondary research encompassing peer-reviewed literature, patent databases, and regulatory filings. Quantitative data were rigorously triangulated with financial reports, clinical trial registries, and market intelligence platforms to ensure consistency and reliability.

A structured framework guided segmentation development, aligning product, application, technology, end user, and cell source dimensions with industry-standard taxonomies. Data validation included peer reviews by subject matter experts and cross-referencing of conflicting sources. Regional insights were derived from government publications, trade associations, and on-the-ground correspondents to capture local market nuances. This robust methodology underpins the strategic and actionable insights presented throughout this report.

Synthesis and Future Outlook in Cardiac Tissue Engineering

The evolving cardiac tissue engineering market is poised for significant growth as technological breakthroughs converge with supportive policy frameworks and collaborative ecosystems. While tariff fluctuations and supply chain constraints present short-term challenges, the industry’s adaptive strategies-ranging from domestic manufacturing to modular platforms-are mitigating risks and unlocking new opportunities.

Segmentation analysis underscores the importance of targeting specific product-application-technology combinations that align with clinical demand and regulatory pathways. Regional variations highlight the need for tailored market entry approaches, leveraging local partnerships and infrastructure advantages. As leading companies refine their commercialization strategies and new entrants bring disruptive innovations, the market’s trajectory will be shaped by the ability to deliver safe, effective, and cost-efficient cardiac therapies at scale.

By integrating the insights and recommendations herein, decision-makers can chart a clear course through this complex landscape, accelerating the translation of regenerative technologies into life-altering treatments.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Bioartificial Hearts
      • Partial Hearts
      • Whole Hearts
    • Cardiac Patches
      • Decellularized Patches
      • Electrospun Patches
    • Cardiac Scaffolds
      • Biological Scaffolds
      • Synthetic Scaffolds
    • Injectable Hydrogels
      • Natural Hydrogels
      • Synthetic Hydrogels
  • Application
    • Heart Valve Regeneration
      • Biological Valve Regeneration
      • Mechanical Valve Replacement
    • Myocardial Repair
      • Congenital Defect Repair
      • Post Infarction Repair
    • Vascular Grafting
      • Coronary Artery Bypass
      • Peripheral Vascular Repair
  • Technology
    • 3D Bioprinting
      • Extrusion Based
      • Inkjet Based
      • Laser Assisted
    • Decellularized Matrices
      • Tissue Segment Decellularization
      • Whole Organ Decellularization
    • Stem Cell Therapy
      • Embryonic Stem Cells
      • Induced Pluripotent Stem Cells
      • Mesenchymal Stem Cells
  • End User
    • Biotechnology Companies
    • Hospitals
    • Pharmaceutical Companies
    • Research Institutes
  • Cell Source
    • Allogeneic
      • Donor Cardiomyocytes
      • Donor Stromal Cells
    • Autologous
      • Cardiomyocytes
      • Stromal Cells
    • Xenogeneic
      • Bovine Cells
      • Porcine Cells
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Organovo Holdings, Inc.
  • Tara Biosystems, Inc.
  • InSphero AG
  • Ncardia B.V.
  • NovoHeart, Inc.
  • BioCardia, Inc.
  • BICO Group AB
  • Matricelf, Inc.
  • XylyxBio LLC
  • AxoSim, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cardiac Tissue Engineering Market, by Product Type
8.1. Introduction
8.2. Bioartificial Hearts
8.2.1. Partial Hearts
8.2.2. Whole Hearts
8.3. Cardiac Patches
8.3.1. Decellularized Patches
8.3.2. Electrospun Patches
8.4. Cardiac Scaffolds
8.4.1. Biological Scaffolds
8.4.2. Synthetic Scaffolds
8.5. Injectable Hydrogels
8.5.1. Natural Hydrogels
8.5.2. Synthetic Hydrogels
9. Cardiac Tissue Engineering Market, by Application
9.1. Introduction
9.2. Heart Valve Regeneration
9.2.1. Biological Valve Regeneration
9.2.2. Mechanical Valve Replacement
9.3. Myocardial Repair
9.3.1. Congenital Defect Repair
9.3.2. Post Infarction Repair
9.4. Vascular Grafting
9.4.1. Coronary Artery Bypass
9.4.2. Peripheral Vascular Repair
10. Cardiac Tissue Engineering Market, by Technology
10.1. Introduction
10.2. 3D Bioprinting
10.2.1. Extrusion Based
10.2.2. Inkjet Based
10.2.3. Laser Assisted
10.3. Decellularized Matrices
10.3.1. Tissue Segment Decellularization
10.3.2. Whole Organ Decellularization
10.4. Stem Cell Therapy
10.4.1. Embryonic Stem Cells
10.4.2. Induced Pluripotent Stem Cells
10.4.3. Mesenchymal Stem Cells
11. Cardiac Tissue Engineering Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Hospitals
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. Cardiac Tissue Engineering Market, by Cell Source
12.1. Introduction
12.2. Allogeneic
12.2.1. Donor Cardiomyocytes
12.2.2. Donor Stromal Cells
12.3. Autologous
12.3.1. Cardiomyocytes
12.3.2. Stromal Cells
12.4. Xenogeneic
12.4.1. Bovine Cells
12.4.2. Porcine Cells
13. Americas Cardiac Tissue Engineering Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cardiac Tissue Engineering Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cardiac Tissue Engineering Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Organovo Holdings, Inc.
16.3.2. Tara Biosystems, Inc.
16.3.3. InSphero AG
16.3.4. Ncardia B.V.
16.3.5. NovoHeart, Inc.
16.3.6. BioCardia, Inc.
16.3.7. BICO Group AB
16.3.8. Matricelf, Inc.
16.3.9. XylyxBio LLC
16.3.10. AxoSim, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CARDIAC TISSUE ENGINEERING MARKET MULTI-CURRENCY
FIGURE 2. CARDIAC TISSUE ENGINEERING MARKET MULTI-LANGUAGE
FIGURE 3. CARDIAC TISSUE ENGINEERING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CARDIAC TISSUE ENGINEERING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CARDIAC TISSUE ENGINEERING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CARDIAC TISSUE ENGINEERING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PARTIAL HEARTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE HEARTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ELECTROSPUN PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY NATURAL HYDROGELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC HYDROGELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL VALVE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MECHANICAL VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CONGENITAL DEFECT REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY POST INFARCTION REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CORONARY ARTERY BYPASS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PERIPHERAL VASCULAR REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EXTRUSION BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INKJET BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY LASER ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TISSUE SEGMENT DECELLULARIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE ORGAN DECELLULARIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR CARDIOMYOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR STROMAL CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIOMYOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STROMAL CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BOVINE CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PORCINE CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 107. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 109. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 110. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 111. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 112. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 114. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 115. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 116. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 118. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 119. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 120. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 122. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 123. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 124. CANADA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 125. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 133. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 134. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 136. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 138. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 141. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 216. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 218. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 219. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 220. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 221. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 223. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 224. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 225. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 227. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 228. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 229. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 231. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 232. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 234. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 236. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 237. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 238. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 239. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 241. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 242. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 243. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 244. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 245. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 246. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 247. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 249. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 250. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 270. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 272. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 273. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 274. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 275. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 277. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 278. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 279. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 280. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 281. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 282. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 283. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 285. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 286. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 287. ITALY CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 288. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 290. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 291. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2030 (USD MILLION)
TABLE 293. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2030 (USD MILLION)
TABLE 295. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2030 (USD MILLION)
TABLE 296. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2030 (USD MILLION)
TABLE 297. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2030 (USD MILLION)
TABLE 299. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2030 (USD MILLION)
TABLE 300. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 301. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 303. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 304. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES CARDIAC TISSUE ENGINEERI

Companies Mentioned

The companies profiled in this Cardiac Tissue Engineering market report include:
  • Organovo Holdings, Inc.
  • Tara Biosystems, Inc.
  • InSphero AG
  • Ncardia B.V.
  • NovoHeart, Inc.
  • BioCardia, Inc.
  • BICO Group AB
  • Matricelf, Inc.
  • XylyxBio LLC
  • AxoSim, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.37 Billion
Forecasted Market Value ( USD ) by 2030 $ 17.18 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cardiac Tissue Engineering Market Size, Share & Trends by Material (Scaffold, Stem Cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-user (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029 - Product Image

Cardiac Tissue Engineering Market Size, Share & Trends by Material (Scaffold, Stem Cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-user (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029

  • Report
  • 337 Pages
  • Global
From
Cardiac Tissue Engineering Global Market Report 2025 - Product Image

Cardiac Tissue Engineering Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Tissue Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Tissue Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Tissue Engineering Market by Product Type, Technology, Material, Application, End User - Global Forecast to 2030 - Product Image

Tissue Engineering Market by Product Type, Technology, Material, Application, End User - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Tissue Engineering Market Report 2025 - Product Image

Tissue Engineering Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.